Lisa Anson Buys 399,000 Shares of Redx Pharma Plc (LON:REDX) Stock

Redx Pharma Plc (LON:REDX) insider Lisa Anson purchased 399,000 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were bought at an average cost of GBX 8 ($0.10) per share, with a total value of £31,920 ($40,399.95).

Redx Pharma Stock Performance

LON:REDX opened at GBX 8.25 ($0.10) on Friday. The stock has a 50-day simple moving average of GBX 17.42 and a two-hundred day simple moving average of GBX 21.43. Redx Pharma Plc has a 52-week low of GBX 4 ($0.05) and a 52-week high of GBX 37.90 ($0.48). The company has a debt-to-equity ratio of 527.00, a quick ratio of 1.93 and a current ratio of 1.11. The firm has a market capitalization of £32.09 million, a PE ratio of -82.50 and a beta of -0.53.

About Redx Pharma

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.